Last reviewed · How we verify

NCT04829994

Post-Market Clinical Follow-Up onTVT EXACT® Continence System

Active, enrolled Last updated 13 April 2026
What this trial tests

trial testing Intervention in Stress Urinary Incontinence in 198 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
8 July 2021
Primary endpoint
30 September 2035
28 February 2036

Quick facts

Lead sponsorEthicon, Inc.
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment198
Start date8 July 2021
Primary completion30 September 2035
Estimated completion28 February 2036
Sites8 locations across France, Denmark, Austria, Sweden, Germany, United States

Drugs / interventions tested

Conditions studied

Sponsor

Ethicon, Inc. — full company profile →

Who can join

21 and older, female only, with Stress Urinary Incontinence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this single arm, post market, clinical study is to evaluate the performance of Gynecare TVT EXACT® Continence System in women undergoing retropubic mid-urethral sling surgery for Stress Urinary Incontinence (SUI).

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Intervention

Trials testing the same drug.

Other recruiting trials for Stress Urinary Incontinence

Currently open trials in the same condition.

Other Ethicon, Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04829994.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing